(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 11.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
United Therapeutics's revenue in 2026 is $3,169,800,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $140,838,260,094, with the lowest UTHR revenue forecast at $128,019,346,728, and the highest UTHR revenue forecast at $152,935,578,999. On average, 17 Wall Street analysts forecast UTHR's revenue for 2027 to be $160,915,564,803, with the lowest UTHR revenue forecast at $135,150,397,872, and the highest UTHR revenue forecast at $192,071,466,825.
In 2028, UTHR is forecast to generate $188,463,494,520 in revenue, with the lowest revenue forecast at $141,305,174,157 and the highest revenue forecast at $210,153,775,083.